Hypothesis

A single psilocybin dose transiently boosts glymphatic influx via astrocytic AQP4 polarization, accelerating clearance of maladaptive extracellular proteins (e.g., hyperphosphorylated tau, inflammatory cytokines) from limbic and default mode network (DMN) regions. This clearance creates a permissive microenvironment for synaptic remodeling that consolidates therapeutic learning, thereby linking the short‑lived DMN desynchronization to the months‑long antidepressant benefit.

Mechanistic Rationale

Psilocybin’s 5‑HT2A agonism drives rapid cortical desynchronization, a state associated with increased neuronal excitability and interstitial fluid flow (1). Concurrently, 5‑HT2A activation raises intracellular cAMP in astrocytes, promoting AQP4 phosphorylation and perivascular localization—a key step for glymphatic efficiency (2). Enhanced CSF‑ISF exchange during the acute window would preferentially clear proteinaceous debris that accumulates in stress‑sensitive circuits, reducing synaptic “noise” and lowering the threshold for long‑term potentiation (LTP) driven by psychotherapy‑induced relearning.

Animal work shows that sleep‑dependent glymphatic flux removes tau oligomers and that AQP4 deletion blocks the antidepressant‑like effects of SSRIs (3). Extending this, we posit that psilocybin‑induced AQP4 redistribution mimics the sleep‑glymphatic boost, but occurs during wakefulness, thereby coupling the pharmacological network reset with a clearance‑dependent plasticity phase.

Predictions & Experimental Design

1. Acute glymphatic surge – In healthy volunteers receiving psilocybin (25 mg) versus placebo, dynamic contrast‑enhanced MRI will show a ≥30 % increase in perivascular CSF influx within 2 h post‑dose, correlating with the magnitude of DMN desynchronization (measured by fMRI).
2. Protein clearance biomarker – CSF levels of phosphorylated tau and IL‑6 will drop significantly at 4 h and remain reduced at 24 h only in the psilocybin group.
3. Dependency on glymphatic function – Pretreatment with the AQP4 inhibitor TGN‑020 (acetazolamide) will blunt the psilocybin‑evoked CSF influx and prevent the downstream reduction in CSF biomarkers, while leaving acute DMN changes intact.
4. Long‑term behavioral outcome – In a depression cohort, participants receiving psilocybin plus psychotherapy who also show the greatest early glymphatic response (top quartile) will exhibit significantly larger reductions in MADRS scores at 3 months compared with those showing weak glymphatic response, despite comparable acute DMN decoupling.

A factorial, double‑blind, crossover design (N = 60) with fMRI, arterial spin labeling, CSF sampling, and clinical scales would test these predictions. The key falsifiable claim is that blocking glymphatic influx abolishes the enduring antidepressant effect without affecting the acute network disruption.

Potential Outcomes

• Support: Demonstrated psilocybin‑driven AQP4‑mediated CSF flow, correlated biomarker clearance, and glymphatic‑dependent therapeutic persistence would reposition DMN desynchronization as a permissive trigger rather than the curative mechanism.
• Refutation: If AQP4 inhibition fails to alter CSF biomarker trajectories or long‑term mood outcomes despite normalizing acute DMN changes, the hypothesis would be falsified, steering focus toward alternative plasticity pathways (e.g., mTOR‑dependent spine growth).

This framework links neuropharmacology, fluid dynamics, and synaptic remodeling, offering a concrete, testable route to explain why a fleeting brain state can yield lasting clinical relief.